92 related articles for article (PubMed ID: 34862448)
1. Virucidal efficacy of guanidine-free inactivants and rapid test buffers against SARS-CoV-2.
Davies K; Arnold U; Buczkowski H; Burton C; Welch SR; Green N; Strachan R; Beetar-King T; Spencer P; Hettiarachchi N; Hannah MJ; Jones M; Cane PA; Bruce CB; Woodford N; Roberts ADG; Killip MJ
Sci Rep; 2021 Dec; 11(1):23379. PubMed ID: 34862448
[TBL] [Abstract][Full Text] [Related]
2. Collection and transportation of SARS-CoV-2 and influenza A virus diagnostic samples: Optimizing the usage of guanidine-based chaotropic salts for enhanced biosafety and viral genome preservation.
Komu JG; Jamsransuren D; Matsuda S; Ogawa H; Takeda Y
Biochem Biophys Res Commun; 2024 Jun; 715():149994. PubMed ID: 38692139
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of stability and inactivation methods of SARS-CoV-2 in context of laboratory settings.
Widera M; Westhaus S; Rabenau HF; Hoehl S; Bojkova D; Cinatl J; Ciesek S
Med Microbiol Immunol; 2021 Aug; 210(4):235-244. PubMed ID: 34196781
[TBL] [Abstract][Full Text] [Related]
4. Effective
Davies K; Buczkowski H; Welch SR; Green N; Mawer D; Woodford N; Roberts ADG; Nixon PJ; Seymour DW; Killip MJ
J Gen Virol; 2021 Apr; 102(4):. PubMed ID: 33913803
[TBL] [Abstract][Full Text] [Related]
5. Analysis of Inactivation of SARS-CoV-2 by Specimen Transport Media, Nucleic Acid Extraction Reagents, Detergents, and Fixatives.
Welch SR; Davies KA; Buczkowski H; Hettiarachchi N; Green N; Arnold U; Jones M; Hannah MJ; Evans R; Burton C; Burton JE; Guiver M; Cane PA; Woodford N; Bruce CB; Roberts ADG; Killip MJ
J Clin Microbiol; 2020 Oct; 58(11):. PubMed ID: 32839250
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the SARS-CoV-2 Inactivation Efficacy Associated With Buffers From Three Kits Used on High-Throughput RNA Extraction Platforms.
Thom RE; Eastaugh LS; O'Brien LM; Ulaeto DO; Findlay JS; Smither SJ; Phelps AL; Stapleton HL; Hamblin KA; Weller SA
Front Cell Infect Microbiol; 2021; 11():716436. PubMed ID: 34604108
[TBL] [Abstract][Full Text] [Related]
7. Virucidal activity of SARS-CoV-2 rapid antigen extraction buffers.
Conzelmann C; Weil T; Olari LR; Gilg A; Rauch L; Albers DPJ; Groß R; Müller JA; Münch J
J Clin Virol; 2022 Feb; 147():105062. PubMed ID: 34995991
[TBL] [Abstract][Full Text] [Related]
8. Antiviral efficacy of personal care formulations against Severe Acute Respiratory Syndrome Coronavirus 2.
Mukherjee S; Vincent CK; Jayasekera HW; Yekhe AS
Infect Dis Health; 2021 Feb; 26(1):63-66. PubMed ID: 33012695
[TBL] [Abstract][Full Text] [Related]
9. Assessment of inactivation procedures for SARS-CoV-2.
Auerswald H; Yann S; Dul S; In S; Dussart P; Martin NJ; Karlsson EA; Garcia-Rivera JA
J Gen Virol; 2021 Mar; 102(3):. PubMed ID: 33416462
[TBL] [Abstract][Full Text] [Related]
10. Comparative effects of viral-transport-medium heat inactivation upon downstream SARS-CoV-2 detection in patient samples.
Thompson JL; Downie Ruiz Velasco A; Cardall A; Tarbox R; Richardson J; Clarke G; Lister M; Howson-Wells HC; Fleming VM; Khakh M; Sloan T; Duckworth N; Walsh S; Denning C; McClure CP; Benest AV; Seedhouse CH
J Med Microbiol; 2021 Mar; 70(3):. PubMed ID: 33734960
[No Abstract] [Full Text] [Related]
11. Efficacy Validation of SARS-CoV-2-Inactivation and Viral Genome Stability in Saliva by a Guanidine Hydrochloride and Surfactant-Based Virus Lysis/Transport Buffer.
Komu JG; Jamsransuren D; Matsuda S; Ogawa H; Takeda Y
Viruses; 2023 Feb; 15(2):. PubMed ID: 36851723
[TBL] [Abstract][Full Text] [Related]
12. Comparison of four commercial, automated antigen tests to detect SARS-CoV-2 variants of concern.
Osterman A; Iglhaut M; Lehner A; Späth P; Stern M; Autenrieth H; Muenchhoff M; Graf A; Krebs S; Blum H; Baiker A; Grzimek-Koschewa N; Protzer U; Kaderali L; Baldauf HM; Keppler OT
Med Microbiol Immunol; 2021 Dec; 210(5-6):263-275. PubMed ID: 34415422
[TBL] [Abstract][Full Text] [Related]
13. Potential False-Negative Nucleic Acid Testing Results for Severe Acute Respiratory Syndrome Coronavirus 2 from Thermal Inactivation of Samples with Low Viral Loads.
Pan Y; Long L; Zhang D; Yuan T; Cui S; Yang P; Wang Q; Ren S
Clin Chem; 2020 Jun; 66(6):794-801. PubMed ID: 32246822
[TBL] [Abstract][Full Text] [Related]
14. Inactivation of foot-and-mouth disease virus A/IRN/8/2015 with commercially available lysis buffers.
Wood BA; Mioulet V; Henry E; Gray A; Azhar M; Thapa B; Diederich S; Hoffmann B; Beer M; King DP; Eschbaumer M
J Virol Methods; 2020 Apr; 278():113835. PubMed ID: 32035122
[TBL] [Abstract][Full Text] [Related]
15. Virucidal effect of monogalactosyl diacylglyceride from a green microalga, Coccomyxa sp. KJ, against clinical isolates of SARS-CoV-2 as assessed by a plaque assay.
Hayashi K; Asai S; Umezawa K; Kakizoe H; Miyachi H; Morita M; Akaike T; Kuno H; Komatsu S; Watanabe T; Kawahara T
J Clin Lab Anal; 2022 Jan; 36(1):e24146. PubMed ID: 34837712
[TBL] [Abstract][Full Text] [Related]
16. Virus Inactivation by Formaldehyde and Common Lysis Buffers.
Seeburg U; Urda L; Otte F; Lett MJ; Caimi S; Mittelholzer C; Klimkait T
Viruses; 2023 Aug; 15(8):. PubMed ID: 37632035
[TBL] [Abstract][Full Text] [Related]
17. Ethanol Susceptibility of SARS-CoV-2 and Other Enveloped Viruses.
Nomura T; Nazmul T; Yoshimoto R; Higashiura A; Oda K; Sakaguchi T
Biocontrol Sci; 2021; 26(3):177-180. PubMed ID: 34556620
[TBL] [Abstract][Full Text] [Related]
18. Tergitol-15-S-9 inactivates SARS-CoV-2 and boosts immunoassay signals.
Berg MG; Israeli E; Quaco E; Cloherty GA; Hemken PM
Biotechniques; 2021 Jul; 71(1):370-375. PubMed ID: 34139879
[TBL] [Abstract][Full Text] [Related]
19. Antiviral Activity of the Propylamylatin
Brown AN; Strobel G; Hanrahan KC; Sears J
Viruses; 2021 Mar; 13(3):. PubMed ID: 33807769
[TBL] [Abstract][Full Text] [Related]
20. Comparative evaluation of four rapid SARS-CoV-2 antigen detection tests using universal transport medium.
Weitzel T; Legarraga P; Iruretagoyena M; Pizarro G; Vollrath V; Araos R; Munita JM; Porte L
Travel Med Infect Dis; 2021; 39():101942. PubMed ID: 33278609
[No Abstract] [Full Text] [Related]
[Next] [New Search]
